首页/数据集/mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer

mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer

ChEBI2015-04-21 更新2026-07-21 收录

HER2阳性乳腺癌

靶向治疗生物标志物

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-55005 数据链接链接失效反馈

官方服务：

资源简介：

mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer

应用场景：

创建时间：

2015-04-21

HER2阳性乳腺癌

治疗反应生物标志物

Trastuzumab, a humanized monoclonal antibody directed to the HER2 protein, is the standard-of-care treatment for patients with HER2 positive breast cancer, reducing the risk of relapse and death in pa

NIAID Data Ecosystem100

Additional file 4 of WFIKKN2 is secreted and elevated in blood plasma of HER2-positive breast cancer patients – implications in cancer surveillance and recurrence monitoring

HER2阳性乳腺癌

生物标志物监测

Supplementary Material 4: Supplementary Table S3

DataCite Commons2025-11-06 更新70

Gene expression profiling of primary HER2-positive breast cancers before and after brief exposure to single agent neoadjuvant trastuzumab

HER2阳性乳腺癌

基因表达谱分析

Tumor incisional biopsies were obtained at baseline and after brief-exposure to single-agent trastuzumab from patients enrolled on the TRastuzumab-UPfront-in-HER2-positive-locally-advanced- BC (TRUP)

NIAID Data Ecosystem50

Drug screening and genomic analyses of HER2 positive breast cancer cell lines reveal predictors for treatment response [CGH]. Homo sapiens

HER2阳性乳腺癌

药物反应预测

Thirteen HER2 positive breast cancer cell lines were screened with 22 commercially available compounds, mainly targeting proteins in the ErbB2 signaling pathway, and the molecular mechanisms related t

NIAID Data Ecosystem80

Additional file 2 of Circulating tumor DNA and Response Evaluation Criteria In Solid Tumors: ctDNA-RECIST proof-of-concept in HER2-positive metastatic breast cancer

液体活检疗效监测

HER2阳性乳腺癌

Supplementary Material 2.

Figshare2026-01-20 更新60